news:: Drug Discovery in Academia
Back to Drug Discovery in Academia

CHDI Foundation Inc

Alex Kiselyov, PhD
Alex Kiselyov has spent over fifteen years in combinatorial chemistry, structure-based drug design, drug discovery, development, cGMP and preclinical services with Amgen, ImClone, ChemDiv and deCODE. He held positions of increasing responsibility at each company. Alex managed multiple preclinical programs in the areas of oncology, inflammation, cardiovascular disorders and cognition. These efforts yielded three clinical candidates. Alex’s primary expertise and interests include enabling technologies for drug discovery in both Chemistry and Biology, rational approach to development of allosteric modulators and inhibitors of protein-protein interaction in the areas of neurodegeneration and cognition, and elucidation of the origins of life on Earth.

Alex received his PhD in Synthetic Organic Chemistry from Georgia State University. He carried out post-doctoral training at the Ben May Institute for Cancer Research at the University of Chicago and Columbia University. He is a member of the Chemical Biology and Drug Design editorial board. Alex joined CHDI in 2010.

CHDI Foundation, Inc.
CHDI Foundation, Inc. is a privately-funded, not-for-profit, virtual biotech company that is exclusively dedicated to rapidly discovering and developing therapies that slow the progression of Huntington's disease (HD). Our scientists work closely with a network of more than 600 researchers in academic and industrial laboratories around the world in the pursuit of these novel therapies, providing project management to ensure that our common goals remain in focus. This helps bridge the translational gap that often exists between academic and industrial research pursuits that adds costly delays to therapy development. In its role as a collaborative enabler, CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as rapidly as possible. Our activities extend from exploratory biology to the identification and validation of therapeutic targets, and from drug discovery and development to clinical studies and trials. More information about CHDI can be found at

Share This Information